Chemical industry in Japan

Europe’s largest fully hydrogen‑compatible gas turbine will be trialled in Lingen, testing up to 100% hydrogen fuel supplied by on‑site electrolysers to inform flexible backup generation.

Revenue rose 22% to $3,238m; epcoritamab approved in Europe and Japan; two Phase‑3 starts for petosemtamab in CRC; multiple Phase‑3 topline readouts were positive.

Company reverses planned exit to retain and renovate Kagawa Plant capacity for pitch- and needle-coke; production pause H2 FY2027, restart H2 FY2028; ~¥9.0bn provision reversal expected.

Sales rose 13.2% to ¥2,037.1bn; core operating income jumped 60.9% to ¥202.8bn while net income fell 18.1% to ¥90.2bn. Full-year revenue and profit forecasts were raised.

Industry investment and policy support sustain demonstrations across blast‑furnace retrofits, DRI–ESF, and electrochemical routes while economics and infrastructure shape deployment timing.

Bought 100% of shares for 20,000 million yen to reinforce electronics/semiconductor materials and expand specialty-chemicals portfolio using GOO Chemical’s formulation and photosensitive technologies.

Revenue rose ~4.3% excl. currency/energy; Electronics and Industrial Merchant led growth. Record investments, first €1bn buyback tranche launched and 2026–27 outlook confirmed.

Revenue +8.4% AER; core operating profit +11.2% AER; ORZEYFUL approved in US/Japan/China; MIMRYLO launched in US; zasocitinib accepted for FDA Priority Review; FY outlook raised for FX.

Signed a Sept 25, 2026 agreement to join a global CDMO alliance for cell and gene therapy, aiming to expand manufacturing support, quality tools and cross-region collaboration.

NEDO‑selected R&D (FY2026–FY2028) will integrate quantum computing and AI to accelerate materials discovery and validate simulations with experiments across batteries, optics, superconductors and colorants.